Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kimberly Rosko"'
Autor:
Marcella Ruddy, Lori A. Mixson, Marc K. Hellerstein, Kimberly Rosko, Carine Beysen, Timothy Riiff, Scott M. Turner, Aubrey Stoch, Elizabeth Murphy
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 315(1)
Fructose feeding increases hepatic de novo lipogenesis (DNL) and is associated with nonalcoholic fatty liver disease. Little is known, however, about individual variation in susceptibility to fructose stimulation of DNL. In this three-period crossove
Autor:
John A. Wagner, Kimberly Rosko, Hankun Li, Chodakewitz Jeffrey A, Carol Addy, Susie Li, Andrea Maes, Amy O. Johnson-Levonas, Patricia Jumes, S. Aubrey Stoch
Publikováno v:
The Journal of Clinical Pharmacology. 49:1228-1238
This study assessed the potential pharmacokinetic interaction and safety/tolerability of taranabant and phentermine coadministration. This was a randomized, double-blind, 3-panel, fixed-sequence study in healthy participants. Panels A, B, and C evalu
Autor:
D. Euan MacIntyre, Yue Feng, Lauren P. Shearman, Xiao-Ming Guan, Mark T. Goulet, Christopher W. Plummer, Sharon Tong, Quang Truong, D. Sloan Stribling, Donald J. Marsh, Junying Wang, Hong Yu, Kimberly Rosko, Sander G. Mills, Paul E. Finke, Alison M. Strack, Stephanie K. Spann, L. H. T. Van Der Ploeg, Shrenik K. Shah, Douglas J. MacNeil, Ramon E. Camacho, Joseph M. Metzger, William K. Hagmann, Tung M. Fong
Publikováno v:
European Journal of Pharmacology. 579:215-224
We document in vitro and in vivo effects of a novel, selective cannabinoid CB 1 receptor inverse agonist, Imidazole 24b (5-(4-chlorophenyl)- N -cyclohexyl-4-(2,4-dichlorophenyl)-1-methyl-imidazole-2-carboxamide). The in vitro binding affinity of Imid
Autor:
Tung M. Fong, Helen E. Armstrong, Thomas J. Lanza, Sookhee Ha, Julie Lao, James P. Jewell, Quang Truong, Lauren P. Shearman, Vincent J. Colandrea, Grace M. Quaker, William K. Hagmann, Guthikonda Ravi N, D. Sloan Stribling, Junying Wang, Chun-Pyn Shen, Sherry Xu, Linus S. Lin, Amy Galka, Xinchun Tong, Mark T. Goulet, Shrenik K. Shah, Linda L. Chang, Lex H.T. Van der Ploeg, Alison M. Strack, Jing Chen, Kimberly Rosko
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:2184-2187
Sulfonamide analogues of the potent CB1R inverse agonist taranabant were prepared and optimized for potency and selectivity for CB1R. They were variably more potent than the corresponding amide analogues. The most potent representative 22 had good ph
Autor:
Xinchun Tong, Yue Feng, Lauren P. Shearman, William K. Hagmann, Koppara Samuel, Jing Chen Xiao, Shrenik K. Shah, Hongbo Qi, Junying Wang, Sanjeev Kumar, Kimberly Rosko, Tung M. Fong, Wenji Yin, Ping Liu, D. Sloan Stribling, Linus S. Lin, Alison M. Strack, Chun-Pyn Shen, Julie Lao, Donald J. Marsh, James P. Jewell, Lex H.T. Van der Ploeg, Thomas J. Lanza, Mark T. Goulet, Suoyu S. Xu
Publikováno v:
Journal of Medicinal Chemistry. 49:7584-7587
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization proces
Autor:
Bing Gao, John A. Wagner, Eseng Lai, Jules I. Schwartz, Stefan Zajic, Jon L. Ruckle, Mark Stroh, Fang Liu, Alan J. Meehan, Kimberly Rosko
Publikováno v:
Cardiovascular therapeutics. 27(4)
Laropiprant (LRPT), a prostaglandin D(2) receptor-1 antagonist shown to reduce niacin-induced flushing symptoms, has been combined with niacin for treatment of dyslipidemia. This open-label, randomized, 2-period crossover study assessed the pharmacok
Autor:
Linus S, Lin, Thomas J, Lanza, James P, Jewell, Ping, Liu, Shrenik K, Shah, Hongbo, Qi, Xinchun, Tong, Junying, Wang, Suoyu S, Xu, Tung M, Fong, Chun-Pyn, Shen, Julie, Lao, Jing Chen, Xiao, Lauren P, Shearman, D Sloan, Stribling, Kimberly, Rosko, Alison, Strack, Donald J, Marsh, Yue, Feng, Sanjeev, Kumar, Koppara, Samuel, Wenji, Yin, Lex H T, Van der Ploeg, Mark T, Goulet, William K, Hagmann
Publikováno v:
Journal of medicinal chemistry. 49(26)
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization proces